Myriad Genetics Acquires Patent on Another Breast Cancer-Linked Gene
By Ayesha Ahmad,
BioNews
| 01. 23. 2012
Myriad Genetics, a leading US molecular diagnostic company, has been granted exclusive rights to an analysis of the RAD51C gene. Mutations of the gene have been associated with an increased risk for hereditary breast and ovarian cancer and the company now hopes to develop a commercial test for RAD51C.
Mark Capone, president of Myriad, said: 'This intellectual property will enhance our ability to provide patients and health care providers important information on a patient's predisposition to hereditary breast and ovarian cancer'.
Read more...
Image via Flickr.
Related Articles
By Gemma Conroy, Nature | 06.27.2024
Image by Robina Weermeijer from Unsplash
A molecular-editing tool that’s small enough to be delivered to the brain shuts down the production of proteins that cause prion diseases, a rare but deadly group of neurodegenerative disorders.
The system — known...
By Editorial Staff, The Lancet | 07.20.2024
Image by DrKontogianniIVF from Wikimedia Commons
Despite major advances in securing sexual and reproductive rights globally, one aspect is continually neglected: infertility. Evolving gender norms and financial precariousness have led to delayed childbearing, which increases infertility in both males and...
By Julia Black and Margaux MacColl, The Information [cites CGS' Katie Hasson] | 07.19.2024
When venture capitalist Jack Abraham first began dating his wife, Gabriella Massamillo, he insisted on one condition: that when they were ready to have children, she’d be willing to conceive using in vitro fertilization. Abraham had lost both his mother...
By Robert Resta, The DNA Exchange | 07.22.2024
Medical geneticists and genetic counselors have an often complicated and at times tense relationship with people with disabilities, their families, advocates, and scholars. Geneticists are strong advocates and supporters for all of their patients, regardless of their abilities and disabilities...